The ability of the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 to prevent neuronal degeneration in the rat striatum and hippocampus caused by intracerebral injection of excitotoxins has been examined. Excitotoxic damage was assessed after 7 d, using histological and biochemical
[choline acetyltransferase (ChAT) glutamate decarboxylase (GAD)] measurements. Systemically administered MK-801 was found to protect against neurodegeneration caused by NMDA (200 nmol) and the naturally occurring NMDA receptor agonist quinolinate (120-600 nmol) but not against that induced by kainate (5 nmol) or a-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA; 50 nmol), indicating a selectivity for NMDA receptormediated neuronal loss. Neurotoxicity caused by NMDA (200 nmol) or quinolinate (200 nmol) was prevented by MK-801 (l-10 mg/kg, i.p.) administered in a single dose affer excitotoxin injection.
In the striatum, significant protection of cholinergic neurons (assessed by ChAT measurements) was observed when MK-801 was given up to 5 hr after injection of NMDA or quinolinate, whereas protection of GABAergic neurons (assessed by GAD measurements) was obtained up to 2 hr. The results suggest that GABAergic neurons degenerate more rapidly than cholinergic neurons. The competitive NMDA receptor antagonist 3-[( f)-Bcarboxypiperazin-4-yll-propyl-1 -phosphonate (100 mg/kg, i.p.) gave partial protection of striatal neurons when administered 1 hr after quinolinate injection.
In the rat hippocampus, administration of 10 mg/kg MK-801 i.p. 1 hr after quinolinate injection caused almost complete protection of pyramidal and granule neurons, whereas the degeneration of CA3/CA4 pyramidal neurons caused by kainate injection was unaffected. These observations indicate that neurons in rat striatum and hippocampus do not die as an immediate consequence of exposure to high concentrations of NMDA agonists but that a delayed process is involved that requires NMDA receptor activation.
In this respect, intracerebral injections of NMDA agonists may mimic the pathological changes that are thought to occur in the brain following periods of cerebral ischemia, where delayed neuronal degeneration occurs.
Neurons of the mammalian CNS degenerate when exposed to abnormally high concentrations of excitatory amino acids such as rglutamate and L-aspartate (Lucas and Newhouse, 1957; Olney et al., 197 1 ). An overstimulation of receptors that normally mediate the excitatory effects of these neurotransmitters (and are located on the dendrites of vulnerable neurons) is proposed as the mechanism by which neurons die (Olney et al., 197 l) , and the term "excitotoxicity" has been coined to describe this phenomenon (Olney, 1974) . Excitatory amino acid receptors have been divided into 3 subtypes named after the prototypical agonists, N-methyl-D-aspartate (NMDA), quisqualate, and kainate (Watkins and Evans, 198 1; Foster and Fagg, 1984) . Studies with selective agonists indicate that excitotoxic effects occur following activation of each receptor subtype (Schwartz et al., 1978; Morgan, 1987) . Injection of excitotoxins directly into the CNS has been used to cause discrete "axon-sparing" lesions of brain regions and to provide animal models of human neurodegenerative disorders (Coyle and Schwartz, 1976; McGeer and McGeer, 1976; Fuxe et al., 1983) . Thus, excitotoxic lesions in the rat striatum reproduce many of the morphological and biochemical changes that occur in the basal ganglia of Huntington's disease victims (Fuxe et al., 1983) . However, it is questionable whether acute injections of excitotoxins can provide animal models of degenerative states such as Huntington's disease that evolve over a period of years. In many respects direct excitotoxin injections reproduce more closely the pathological changes that occur during cerebral ischemia, when massive acute elevations of extracellular levels of excitatory amino acids are observed in the CNS (Benveniste et al., 1984; Hagberg et al., 1985) . The neuronal degeneration that results occurs particularly in brain regions possessing a high density of NMDA receptors (see Wieloch, 1985) and can be reduced by administration of selective NMDA receptor antagonists (Rothman, 1984; Simon et al., 1984; Gill et al., 1987a, b) . These observations suggest that an excitotoxic mechanism involving NMDA receptors may be a cause of ischemia-induced neuronal degeneration. An interesting feature of the neuronal degeneration resulting from periods of global forebrain ischemia is that susceptible neurons may not die immediately but degenerate at times as long as 24-48 hr after the initial insult (Kirino, 1982; Pulsinelli et al., 1982; Gill et al., 1987a) . Recent evidence indicates that such delayed neuronal degeneration may also occur in patients who are resuscitated following cardiopulmonary arrest (Petit0 et al., 1987) .
Experiments in this laboratory have shown that the novel anticonvulsant (+)-5-methyl-10,ll -dihydro-SH-dibenzo-[a,d]cyclohepten-5, lo-imine maleate (MK-80 1) is a potent, se-lective, and noncompetitive NMDA receptor antagonist (Wong et al., 1986) . Upon systemic administration, MK-80 1 prevents the loss of striatal and hippocampal neurons in the rat caused by direct injection of NMDA (Foster et al., 1987a) and protects against the degeneration of hippocampal neurons in the gerbil and rat caused by a brief period of forebrain ischemia (Gill et al., 1987a, b) . In the present series of experiments we have examined the specificity of MK-801
for NMDA receptor-mediated neurodegenerative events by assessing its ability to prevent neuronal degeneration in the rat brain caused by direct injection ofthe endogenous NMDA receptor agonist quinolinate (Stone and Perkins, 1981; Schwartz et al., 1983) , the selective quisqualate receptor agonist m-cr-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA, Krogsgaard-Larsen et al., 1980) and the kainate receptor agonist, kainate. In addition, we have used MK-801 to evaluate the possibility that, like the situation in cerebral ischemia, the neuronal degeneration that occurs following direct excitotoxin injection occurs by a delayed process. Some of these results have appeared previously in abstract form .
Dowex 1 x 8 chloride resin were prepared in Pasteur pippettes and washed with 1 ml of distilled water. A sample (0.4 ml) of the reaction mixture was applied onto a column followed by a 1 ml wash with distilled water, and the total eluate (1.4 ml) was collected in a 20 ml mastic scintillation vial. This orocedure was ontimal for elutina 14C-kCh with retention of 14C-acetyl coenzyme A-on the column.-Alter addition of 10 ml scintillation fluid and thorough mixing, radioactivity in the samples was determined by scintillation counting in a beta count--_ Cl.
GAD assay. A modification of the 14C0,-trapping method of Wilson et al. (1972) was used to determine GAD activity. Fifty milliliters of striatal homogenate was incubated in duplicate for 30 min at 37°C in a solution containing 25 mM potassium phosphate buffer (pH 6.8), 1 mM EDTA, 1 mM 2-mercaptoethanol, 0.2% Triton X-100, 0.5 mM pyridoxal phosphate, and 5 mM L-[ 1 J4C]-glutamate (diluted to a specific activity of 0.2 mCi/mmol) in a final volume of 100 ~1. Blank values were obtained by substituting 50 ~1 of 50 mM Tris-HCl buffer (pH 7.4), 0.2% Triton X-100 for the striatal homogenate. The assay was performed in 5 ml polypropylene tubes and I"CO, produced was trapped in Whatman GF/B filters soaked with 200 ~1 of 1 M hyamine hydroxide in methanol contained within plastic scintillation minivials linked to the assay tubes by a sleeve of rubber tubing. The reaction was stopped by injection of 200 ~1 of 10 mM acetic acid in methanol through the rubber sleeve via a syringe, and the tubes were left at room temperature overnight to ensure complete trapping of 14C0, produced. After addition of 4 ml scintillation fluid to the minivials, radioactivity was determined by scintillation counting in a beta counter.
Materials and Methods Stereotaxic injections and drug treatment
For the majority of experiments, male Sprague-Dawley rats (250-350 gm) were anesthetized with Equithesin (82 ml) Nembutal, 42.5 gm chloral hydrate, 21.26 gm MgSO,, 396 ml propane-1,2-diol, 100 ml ethanol in 1 liter of distilled water; 3.75 ml/kg i.p.) and placed in a Kopf stereotaxic frame. An incision was made in the scalp and the surface of the skull exposed. Excitotoxin injections were made into the right striaturn or hippocampus by means ofa 28-gauge stainless steel needle linked to a Hamilton syringe. Injections were made via a l-2 mm diameter hole made in the skull using a small hand drill. For the striatum, coordinates of injection were A 0.5 mm from bregma, L 2.6 mm from midline, and V 4.4 mm from dura. For the hippocampus, coordinates of injection were A -3.0 mm from bregma, L 2.0 mm from midline, and V 3.0 mm from dura. Quinolinate, NMDA, kainate, and AMPA were dissolved in 1 M NaOH, the pH adjusted to 7.4 with 1 M HCl and brought to the required volume with a solution of 10 mM sodium phosphate buffer (pH 7.4) in 0.9% saline. Excitotoxins were injected in a volume of 1 ~1 delivered over a period of 2 min, and the injection needle was left in place for a further 1.5 min to allow diffusion of the injected solution. After the scalp was apposed with wound clips, animals were allowed to recover for 7 d. In one group of animals, anesthesia was induced and maintained by a mixture of 2% isoflurane/70% N,0/30% 0, during intrastriatal injection of quinolinate.
MK-80 1 or 3-[(+)-2-carboxypiperazin-4-yl]-propyl-l-phosphonate (CPP) was dissolved in 0.9% saline and administered as a single injection i.p. (1 ml/kg body weight) at the designated times before or after excitotoxin injection.
Enzyme measurements
Seven days after excitotoxin injection, rats were killed and their brains removed; both striata were dissected and frozen on dry ice. After measuring the wet weight, individual striata were sonicated for 10 set in 20 vol (wt/vol) of 50 mM Ttis-HCl (pH 7.4), 0.2% Triton X-100. Aliquots of these homogenates were then taken for determination of choline acetyltransferase (ChAT) and glutamate decarboxylase (GAD) activities.
ChAT assay. A modification of the method of Bull and OderfeldNovak (197 1) was used to measure ChAT activity. A 10 ~1 sample of striatal homogenate was incubated in duplicate for 20 min at 37°C in a solution containing 300 mM NaCl, 6 rnhr choline chloride, 75 PM physostigmine, 50 mM sodium phosphate buffer (pH 7.0), 0.5 mg/ml BSA, and 50 PM [ 1 J4C]acetyl coenzyme A (diluted to a specific activity of 1 mCi/mmol) in a final volume of 100 ~1. Blank values were obtained by replacing the homogenate with 10 ~1 of 50 mM Tris-HCl (pH 7.4) 0.2% Triton X-100. The incubation was terminated by the addition of 0.4 ml ice-cold distilled water and the tubes placed on ice. The 14C-ACh produced was separated from unreacted 14C-acetyl coenzyme A by ionexchange chromatography. Small (approximately 2 cm) columns of
The results of the enzyme assays are expressed as the percentage reduction of activity in the injected versus contralateral striatum, calculated using the equation [(D-I)lD] x 100, where D is dpm produced in homogenate from the contralateral side and I is dpm produced in homogenate from the injected side, after subtraction of blank values.
Histology
Seven days after excitotoxin injection, rats were perfused transcardially with 0.9% saline followed by a solution of 10% formaldehyde containing 5% (wt/vol) sucrose under deep Equithesin anesthesia. The brains were removed and placed in 5% formaldehyde containing 30% (Wuvol) sucrose for at least 2 d, after which 40 pm sections were cut using a freezing sledge microtome and stained with cresyl violet. 
Results
Both neurochemical and histological methods were used to evaluate neuronal degeneration in the rat striatum or hippocampus occurring 7 d after local injection of quinolinate, NMDA, kainate, or AMPA. A quantitative assessment of the loss of striatal cholinergic and GABAergic neurons was made by measuring the activities of the respective marker enzymes ChAT and GAD in striatal homogenates. The morphology of the injected striaturn or hippocampus was assessed by light microscopy in cresyl violet-stained coronal brain sections.
Effects of MK-801 on neurodegeneration caused by quinolinate and NMDA MK-801 administered before excitotoxin injection Enzyme measurements. In control animals, intrastriatal injection of 120, 200, 300, or 600 nmol quinolinate resulted in a dose-related reduction of both ChAT and GAD activities in the injected striatum compared with the contralateral, uninjected side (Table 1) . At the lowest dose of 120 nmol quinolinate, the percentage reduction of GAD activity was greater than that for ChAT (p < 0.01, paired t test), indicating a preferential vul- nerability of GABAergic versus cholinergic neurons. Pretreatment of rats with 10 mg/kg MK-801 (i.p.) 1 hr prior to quinolinate injection almost completely prevented the reductions of ChAT and GAD activities at each dose of quinolinate (Table  1) . To investigate the doseresponse relationship of this protection by MK-80 1, lower doses of the drug were tested against 120 and 200 nmol quinolinate. With 120 nmol quinolinate, the decrease in ChAT activity was significantly prevented by 3 mg/ kg MK-801, but not 1 mg/kg MK-801, whereas both doses produced significant attenuation of the decrease in GAD activity (Table 1) . In contrast, doses of 1 or 3 mg/kg MK-801 were unable to prevent the reductions of ChAT or GAD activities caused by 200 nmol quinolinate (Table l) , despite the fact (as indicated above) that 10 mg/kg MK-80 1 gave virtually complete protection.
Histology. Injection of 200 or 300 nmol quinolinate into the rat striatum resulted 7 d later in an extensive area of striatal neuron degeneration and gliosis extending for several millimeters around the site of injection (n = 4 in each group). Injection of 10 mg/kg MK-80 1 (i.p.) 1 hr before intrastriatal quinolinate caused essentially complete protection of neuronal loss and prevented gliosis (n = 4 in each group; Fig. 1C ). In the rat hippocampus, injection of 60 nmol quinolinate resulted 7 d later in the degeneration of all hippocampal pyramidal and granule neurons and a marked gliosis within a few millimeters of the injection site (n = 5; Fig. 2B ). MK-801 (10 mg/kg, i.p.) administered 1 hr prior to quinolinate injection prevented gliosis and caused complete protection of hippocampal neurons, except some CA 1 pyramidal cells and dentate granule cells in the immediate proximity of the injection site (n = 5, Fig. 2C ).
MK-801 administered after excitotoxin injection Enzyme measurements. The excitotoxin-induced reduction of
ChAT and GAD activities could be prevented by MK-80 1 administered at various times after excitotoxin injection. As shown in Figure 3A , the reduction of striatal ChAT activity caused by 200 nmol quinolinate was completely prevented by a single 10 mg/kg dose of MK-801 administered i.p. either 1 or 2 hr after quinolinate injection. Partial protection of the decrement in ChAT activity was observed when MK-80 1 was given 5 hr after quinolinate, with no significant protection at 8 or 24 hr. Analysis of the same striatal homogenates for GAD activity indicated partial protection by 10 mg/kg MK-801 at 1 and 2 hi after quinolinate but no difference from control at 5,g, or 24 hr (Fig.   3B ).
Essentially the same pattern of protection by MK-801 was apparent when striatal neuron degeneration was induced by intrastriatal injection of 200 nmol NMDA, a dose that resulted in an equivalent degree of reduction in ChAT and GAD activities as that which occurred following 200 nmol quinolinate (Fig.  4) . Thus, the loss of ChAT activity was attenuated by 10 mg/ kg MK-801 administered 1, 2, or 5 hr, but not 24 hr, after NMDA injection (Fig. 4A) . The loss of GAD activity measured in the same samples was reduced by MK-801 at 1 or 2 hr, but not 5 or 24 hr, after NMDA injection (Fig. 4B) .
The dose-response relationship of protection resulting from delayed administration of MK-80 1 was investigated at a time point of 1 hr after intrastriatal injection of 200 nmol quinolinate (Fig. 5) . With 1, 3, and 10 mg/kg MK-801, a clear dose-dependent protection of the reductions in ChAT and GAD activities caused by quinolinate was apparent. Note that, in contrast to pretreatment of animals with the same doses of MK-801 (see Table l ), a significant effect of the 1 and 3 mg/kg doses was obtained by administration 1 hr after injection of 200 nmol quinolinate.
Histology. The protective effects of delayed MK-80 1 administration against quinolinate-induced neurodegeneration were confirmed histologically. Injection of 120 nmol quinolinate into the striatum of control animals resulted 7 d later in a loss of intrinsic neurons and a marked gliosis for a few millimeters around the injection site (n = 5; Fig. le) . Administration of 10 mg/kg MK-80 1 (i.p.) 1 hr after quinolinate injection resulted in virtually complete protection of striatal neurons in all animals (n = 5; Fig. 1D ). Delayed administration of MK-801 also prevented quinolinate-induced neuronal degeneration in the rat hippocampus. Thus, in 5 animals receiving an intrahippocampal injection of 60 nmol quinolinate followed 1 hr later by 10 mg/kg MK-80 1 (i.p.), 3 had no signs of neuronal loss except for a small number of CA1 and CA4 pyramidal cells in the immediate vicinity of the injection site (Fig. 2D) , whereas the remaining 2 had a small area of CA 1 pyramidal cell degeneration but complete protection of other hippocampal neurons. This was in marked contrast to the extensive degeneration of all hippocampal cells for several millimeters around the site of injection in control animals ( Fig. 2B; see above) .
Effects of MK-801 on striatal neurodegeneration caused by kainate and AMPA The selectivity of MK-80 1 as an antagonist of NMDA receptormediated neuronal degeneration was assessed in the rat striatum by determining its effects on the reductions of ChAT and GAD activities resulting from intrastriatal injection of kainate or AMPA. As shown in Table 2 , intrastriatal injection of 5 nmol kainate resulted 7 d later in an approximately 60% reduction of ChAT and GAD activities in the injected striatum as compared with the contralateral, uninjected side. MK-80 1 (10 mg/ kg, i.p.) given either 1 hr before or 2 or 5 hr after kainate injection was unable to prevent the reductions in ChAT and GAD activities caused by kainate. Intrastriatal injection of 50 nmol AMPA resulted 7 d later in a significantly (p < 0.0 1; paired t test) greater reduction of GAD activity than ChAT activity (Table 2) , indicating a preferential vulnerability of striatal GABAergic neurons to this excitotoxin. Administration of MK-80 1 (10 mg/kg, i.p.) at 1 hr before or 2 or 5 hr after AMPA injection resulted in no significant protection against decreases in ChAT and GAD activities.
The effect of delayed MK-80 1 administration was also tested against kainate-induced neuronal degeneration in the rat hippocampus. Injection of 1 nmol kainate into the dorsal hippocampus in 5 animals resulted in destruction of CA3 and CA4 pyramidal neurons in all animals ( Fig. 2E) and additional involvement of CA 1 neurons in 3 animals. In another group of 5 animals, administration of MK-801 (10 mg/kg, i.p.) 1 hr after kainate injection failed to prevent the loss of CA3 and CA4 pyramidal neurons (Fig. 20 . Effect of CPP on striatal neurodegeneration caused by quinolinate To determine if delayed administration of another selective NMDA receptor antagonist could prevent striatal neurodegeneration caused by quinolinate, the competitive antagonist CPP (Harris, et al., 1986; Lehmann et al., 1987 ) was injected i.p. 1 hr after intrastriatal injection of 200 nmol quinolinate. As shown in Table 3 , administration of 100 mg/kg CPP resulted in significant, but incomplete, protection against the reductions of ChAT and GAD activities caused by quinolinate.
Effect of isoflurane anesthesia An experiment was designed to evaluate the possibility that the ability of delayed administration of MK-801 to protect against quinolinate-induced striatal neurodegeneration was due to an interaction with the surgical anesthetic used. In all of the experiments described so far, excitotoxin injections were made under Equithesin anesthesia, from which rats regain the righting reflex approximately 2 hr after excitotoxin injection. A group of 10 rats was injected with 200 nmol quinolinate into the striatum under 2% isoflurane, 70% N,O, 30% 0, anesthesia. Animals recovered the righting reflex within 30 min and developed behaviors typically observed following unilateral striatal injections of quinolinate (clonic-tonic movements of contralateral forepaws, barrel rotation, etc.-see Foster et al., 1983) . At 2 hr after quinolinate injection, 5 animals were injected i.p. with 10 mg/kg MK-80 1 and the remaining 5 animals remained untreated as controls. As shown in Table 3 , measurement of striatal ChAT and GAD activities in these animals 7 d later indicated a protective effect of MK-80 1 that, although less pronounced, was comparable with that observed when Equithesin was used as an anesthetic (cf: Fig. 3 ).
Discussion
Specificity of MK-801 for NMDA receptor-mediated neurodegeneration Electrophysiological experiments in vitro Wong et al., 1986) and in vivo (Davies et al., 1988) indicate that MK-80 1 is a selective antagonist of NMDA receptor-mediated neuronal depolarization. The present results and those of our previous study (Foster et al., 1987a) demonstrate that MK-80 1 is also a selective antagonist of NMDA receptor-mediated neuronal degeneration in the rat brain. Thus, in the rat striatum MK-80 1 dose-dependently protected against the loss of intrinsic neurons caused by local injection of NMDA (Foster et al., 1987a) and the endogenous NMDA receptor agonist quinolinate (present study). However, striatal neurodegeneration caused by intrastriatal injection of kainate or AMPA could not be prevented by MK-801 at doses and times of administration that were protective with respect to NMDA and quinolinate (Foster et al., 1987a , and present study). In the rat hippocampus, a 10 mg/kg dose of MK-801 almost completely prevented the loss of neurons caused by local injection of NMDA (Foster et al., 1987a) and quinolinate but not that caused by kainate. Thus, when administered systemically in vivo MK-80 1 prevents neuronal degeneration caused by NMDA receptor agonists (NMDA and quinolinate) but not that induced by agonists selective for the quisqualate and kainate subtypes of excitatory amino acid receptors.
A dose of 10 mg/kg MK-80 1 caused virtually complete protection against all doses of quinolinate injected into the striatum. Even at the highest dose of quinolinate (600 nmol), which, in untreated rats, resulted in degeneration of the entire striatum and reduction of ChAT and GAD values to ~4% of control values, pretreatment with 10 mg/kg MK-80 1 maintained ChAT and GAD activities at 9 1 and 82% of control, respectively (see Table 1 ). The blockade of NMDA depolarizations by MK-80 1 in vitro is noncompetitive and insurmountable by further addition of agonist Wong et al., 1986) . MK-80 1 is proposed to act by blocking the open state of the NMDA receptor associated ion channel (Kemp et al., 1987) ; therefore, it does not compete directly with agonists for the receptor. The characteristics of the protection by MK-80 1 of quinolinate-induced neurotoxicity in vivo are consistent with this mechanism of antagonism. (1) only neurodegeneration caused by NMDA receptor agonists (NMDA and quinolinate) was prevented and kainateand AMPA-induced neuronal loss was unaffected by MK-801 administered up to 5 hr after excitotoxin injection; (2) protection of neurons occurred in both striatum and hippocampus (the only brain regions studied); (3) the protection was not equal for all neurons since in the striatum administration of MK-801 5 hr after excitotoxin injection partially protected cholinergic neurons but could not prevent degeneration of GABAergic neurons; (4) the apparent potency of MK-80 1 as an antagonist of neurodegeneration was greater when it was administered after quinolinate injection than before, suggesting that the critical period for protection occurs following quinolinate injection; and (5) protection of neurons by delayed MK-80 1 administration was not due to a specific interaction with the surgical anesthetic used or the length of time animals spent in anesthesia since equivalent results were obtained using Equithesin or isoflurane/N,O/O,.
Therefore, following intracerebral injection of an NMDA re- ceptor agonist, neurons in the striatum or hippocampus do not die as an immediate consequence of NMDA receptor activation, but undergo a delayed form of degeneration that can be prevented by MK-801 administered l-5 hr after excitotoxin injection.
Mechanism of delayed neuronal degeneration What is the mechanism by which NMDA receptor agonists cause delayed degeneration? First, it seems improbable that the delayed degenerative events are due to injected quinolinate or NMDA remaining in the vicinity of the vulnerable neurons over a period of several hours. Following injection of 3H-quinolinate into the striatum, levels of striatal radioactivity decline with a half-life of 22 min and after injection into the hippocampus, only 3% of 3H-quinolinate remains in hippocampal tissue 25 min later (Schwartz et al., 1984) .Thus, it seems unlikely that such low levels of residual quinolinate (or NMDA) could mediate degenerative events that occur as long as 5 hr after injection. Second, quinolinate is not metabolized following intrastriatal or hippocampal injection Schwartz et al., 1984) , ruling out the possibility that an excitotoxic metabolite slowly accumulates. Therefore, one plausible mechanism for these effects is that local injection of an NMDA agonist sets in motion a process that continues over several hours and leads to neuronal death and that this delayed process involves intrinsic neuronal mechanisms, not the exogenous NMDA agonist itself. This idea is supported by experiments in tissue culture which indicate that the continual presence of an excitatory amino acid is not required to produce neuronal degeneration and that pharmacological intervention in the period following a brief exposure to glutamate can prevent neuronal loss .
The fact that neuronal degeneration is prevented by delayed administration of MK-801 (whose selectivity for NMDA receptors is discussed above) indicates that NMDA receptor activation participates in the delayed degenerative process. Furthermore, delayed administration ofthe selective and competitive NMDA receptor antagonist CPP (Harris et al., 1986; Lehmann et al., 1987) which bears no structural similarity to MK-801, also partially prevented quinolinate-induced neurotoxicity (Table 3) further strengthening the argument that the delayed degenerative process requires activation of NMDA receptors and that the neuroprotective effects of MK-80 1 are not due to some unsuspected pharmacological action of this compound. Again, tissue culture experiments support an NMDA receptor involvement since the selective, competitive NMDA antagonist D-2-amino-5phosphonovalerate (D-APS) prevents neurodegeneration when applied to cultured neurons in the period following exposure to glutamate . Our results indicate that the initiation of the delayed degenerative process that is blocked by MK-80 1 specifically requires NMDA receptor activation. Thus, delayed administration of MK-801 did not prevent the degeneration of neurons caused by kainate and AMPA. This suggests that the delayed degenerative process does not result from excessive depolarization of neurons per se (see also since the vulnerable neurons in the striatum and hippocampus can be depolarized by activation of quisqualate and kainate receptors (Collingridge et al., 1983; Herrling et al., 1983) .
At face value, the present results are at variance with the original concepts of the "excitotoxic hypothesis" (Olney, 1974) . When neurons in vitro are chronically exposed to high concentrations of excitatory amino acids, they degenerate rapidly by a process involving entry of Na+, Cl-, and water, resulting in osmotic lysis (Rothman and Olney, 1987) . However, brief exposure of neurons to glutamate or NMDA in vitro results in a Ca*+-dependent form of neurodegeneration (Choi, 1985 (Choi, , 1987 Garthwaite and Garthwaite, 1986 ) which is of a delayed type (Choi, 1985 (Choi, , 1987 and can be blocked by addition of competitive NMDA antagonists in the period following agonist exposure . Therefore, our results in vivo agree with these in vitro studies, and it may be that the degeneration of neurons caused by direct excitotoxin injection in vivo is of the delayed Ca2+-dependent type, rather than the rapid Cl--dependent type.
Our results with selective NMDA agonists and MK-801 indicate that NMDA receptor activation both initiates the delayed process leading ultimately to neuronal death and is essential for its expression. It is possible that the mechanisms underlying these events are the same as those occurring during long-term potentiation or kindling (Goddard et al., 1969; Bliss and Lomo, 1973) . In both cases, evidence indicates that NMDA receptor activation establishes a permanent change in activity at excitatory amino acid-using synapses (Collingridge et al., 1983; Mody and Heinemann, 1987; Stelzer et al., 1987) . A further possibility is that delayed degeneration is a consequence of the preceding loss of inhibitory influences. An early failure of inhibition has been observed in a model of experimental epilepsy where subsequent degeneration of hippocampal neurons occurs (Sloviter, 1987) , and a lack of GABAergic tone has been proposed as the cause of experimentally induced delayed degeneration of neurons in the substantia nigra (Saji and Reis, 1987) . It is therefore interesting to note that in the present studies GABAergic neurons appeared to degenerate earlier than cholinergic neurons in the striatum following quinolinate or NMDA injection. Thus, it is possible that degeneration of cholinergic neurons is secondary to the loss of GABAergic neurons, which usually exert an inhibitory influence upon them.
Delayed degeneration of neurons is a phenomenon observed in animal models of cerebral ischemia (Kirino, 1982; Pulsinelli et al., 1982; Gill et al., 1987a) , and recent evidence suggests that delayed degeneration occurs in the hippocampus of humans following cardiorespiratory arrest (Petit0 et al., 1987) . The delayed death of neurons that occurs in gerbils subjected to a brief period of cerebral ischemia can be prevented by MK-801 administered as a single dose during or up to 24 hr after the initial insult (Gill et al., 1988) . Therefore, the delayed neuronal loss described here in response to intracerebral injection of NMDA agonists may occur by similar mechanisms to those which cause neurodegeneration in cerebral ischemia. It is hoped that further investigation of this delayed degenerative process will shed light on the mechanisms underlying neurodegenerative phenomena in pathological situations and may provide further clues for therapeutic strategies to alleviate them.
